Bill Cara’s Blog for Jul 13, 2012
CTA Trading Desk Morning Report
[7:00am ET] Good morning.
Merck (MRK) is a Cara 100 company based on its strong balance sheet, return on equity, and other peer leading financial metrics.
You may already be aware that, over the past month and 4th best over the past three months, MRK is the 5th best stock performer in the Cara 100.
Why is that?
You’ll find the answer in this article from Benzinga.com:
When Merck’s latest drug, Suveraxant, an insomnia med, has been FDA-approved for the market, it may become the “next best thing” from Big Pharma, and that’s what likely is driving the stock.
Unfortunately, the Value Line report on Merck that was released this week has no mention of Suveraxant.
Besides, at the current price of $42.91, Merck will pay a dividend yield of +4.0% over the next 12 months, so that plus Suxeraxant will let you sleep at night. However, the stock is a tad over-bought presently.
Have a good day.
Good morning, Geoff here.
As I mentioned the last 2 days, this could be a major point in the markets. The US Dollar is breaking out –
Strike 2! 3 strikes and your out.
But, there are also signs of the dollar topping here as well. We need to see how it performs in the next day.
Here is the exact chart of the CRB that I posted on July 2nd and then todays chart:
Have a great trading day!
Here are the 7:00am ET snapshots of the latest equity market trading results for Europe, and futures prices plus 5-minute charts of the futures for S&P 500, 30-year US Treasury Bond, US Dollar index, Gold and Crude Oil.
|Symbol||Name||Last Trade||Change||Related Info|
||21.90 (1.13%)||Components, Chart, More|
||11.40 (0.52%)||Components, Chart, More|
||22.24 (0.71%)||Components, Chart, More|
||78.49 (1.22%)||Components, Chart, More|
||1.98 (0.64%)||Components, Chart, More|
|^OSEAX||OSE All Share||463.79
||5.70 (1.24%)||Components, Chart, More|
||3.75 (1.19%)||Components, Chart, More|
||23.11 (0.38%)||Components, Chart, More|
||44.58 (0.79%)||Components, Chart, More|
||5.00 (0.56%)||Chart, More|
||7.46 (0.53%)||Chart, More|
|GD.AT||Athex Composite Share Price Index||610.70
||10.54 (1.76%)||Chart, More|
The team will check in during the day, reporting in the Discourse when there is a new entry.
Enjoy your day.
Cara 100 Company research notes from brokers
Vad’s Catch of the Day
Kaimu’s Sound Money
Deron’s Daily ETF Analysis
Since the market began selling off over a week ago, the iShares Nasdaq Biotechnology ETF (IBB) has show considerable realative strength to the broad market. While the Nasdaq was losing support of both its 20-day and 50-day moving averages, IBB only undercut its 20-day EMA. Further, IBB quickly regained support of the 20-day EMA after undercutting it sharply yesterday. IBB ended the day near session highs. A volume fueled move above $131.01 could present a buying opportunity in this ETF. We are monitoring IBB closely for a possible long entry.
The commentary above is an excerpt from The Wagner Daily newsletter, which we have been publishing since 2002. Subscribers to the full version receive our exact entry and exit prices for swing trades of the top ETF and stock picks, access to our market timing model, and more. To get started today, sign up for your 30-day risk-free trial to our Wagner Daily stock newsletter or visit our trading blog to learn more about our proven technical trading strategy.
Cara on the Metalminers
Cara on the International Markets
CTA Trading Desk Mid-Day Report
CTA Trading Desk Post-Close Report